PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

被引:32
|
作者
Markowski, Mark C. [1 ]
Chen, Yongmei [2 ]
Feng, Zhaoyong [3 ]
Cullen, Jennifer [2 ]
Trock, Bruce J. [3 ]
Suzman, Daniel [1 ]
Antonarakis, Emmanuel S. [1 ]
Paller, Channing J. [1 ]
Rosner, Inger [2 ]
Han, Misop [3 ]
Walsh, Patrick C. [3 ]
Partin, Alan W. [3 ]
Eisenberger, Mario [1 ]
机构
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA
[2] Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, Bethesda, MD 20814 USA
[3] Johns Hopkins Univ, Dept Urol, Brady Urol Inst, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
Biochemical recurrence; Deferred ADT; Natural history; Post-prostatectomy; PSA cut-point; SALVAGE RADIOTHERAPY; RADIATION-THERAPY; NATURAL-HISTORY; ANTIGEN; PROGRESSION; MORTALITY; DISEASE; POINT;
D O I
10.1016/j.clgc.2019.08.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In men with biochemically-recurrent prostate cancer, prostate-specific antigen doubling time <= 7.5 months, prostate-specific antigen >= 0.5 ng/mL, and Gleason score are independent predictors of metastasis-free survival on multivariable analysis. These data can assist physicians during discussions with patients regarding the risk of developing metastatic disease and for clinical trial planning. Introduction: The aim of this study was to investigate the association of prostate-specific antigen (PSA) values on metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) and PSA doubling time (PSADT) < 12 months. This dataset also reflects an update with longer follow-up of our prior publications on the natural history of BRPC in the absence of treatment. Materials and Methods: In this report, we combined databases from the Center for Prostate Disease Research and Johns Hopkins University (CPDR/JHU). In the CPDR/JHU radical prostatectomy database (30,936 total patients), 656 men with BRPC (> 0.2 ng/mL) after prostatectomy and PSADT < 12 months, who received no adjuvant/salvage androgen deprivation and/or radiation therapy, were prospectively followed until radiologic evidence of metastasis and are included in this analysis. Results: Metastasis occurred in 250 of 656 patients with BRPC (median follow-up, 5 years). PSADT < 7.5 months and Gleason score were independent risk factors for distant metastasis in multivariable analysis. Risk of metastasis increased for PSADT 6.01 to 7.50, 4.51 to 6.0, 3.01 to 4.50, and <= 3.0 months, after adjusting for Gleason score. A PSA value >= 0.5 ng/mL significantly and independently increased risk of metastasis in patients with PSADT < 12 months (hazard ratio, 2.79; 95% confidence interval, 1.47-5.29; P = .001). Conclusions: In men with PSADT < 12 months, PSADT <= 7.5 months, PSA >= 0.5 ng/mL, and Gleason score are independent predictors of MFS on multivariable analysis. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:470 / +
页数:7
相关论文
共 50 条
  • [21] PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
    Roberts, SG
    Blute, ML
    Bergstralh, EJ
    Slezak, JM
    Zincke, H
    MAYO CLINIC PROCEEDINGS, 2001, 76 (06) : 576 - 581
  • [22] Percent free PSA values in men with recurrent cancer following radical prostatectomy question the hypothesis of percent free PSA.
    Vashi, AR
    Wojno, KJ
    Wright, GL
    Schellhammer, PF
    Montie, JE
    JOURNAL OF UROLOGY, 1998, 159 (05): : 236 - 236
  • [23] Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
    A P Doherty
    M Bower
    G L Smith
    R Miano
    E M Mannion
    H Mitchell
    T J Christmas
    British Journal of Cancer, 2000, 83 : 1432 - 1436
  • [24] Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
    Doherty, AP
    Bower, M
    Smith, GL
    Miano, R
    Mannion, EM
    Mitchell, H
    Christmas, TJ
    BRITISH JOURNAL OF CANCER, 2000, 83 (11) : 1432 - 1436
  • [25] Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy
    Schweizer, Michael Thomas
    Zhou, Xian C.
    Wang, Hao
    Yang, Ting
    Shaukat, Farah
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [26] The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy
    Lee, Emerson E.
    Singh, Tanmay
    Hu, Chen
    Han, Misop
    Deville, Curtiland, Jr.
    Halthore, Aditya
    Greco, Stephen
    Phuoc Tran
    DeWeese, Theodore
    Song, Daniel Y.
    PROSTATE, 2023, 83 (02): : 190 - 197
  • [27] Predicting survival of men with recurrent prostate cancer after radical prostatectomy
    Dell'Oglio, Paolo
    Suardi, Nazareno
    Boorjian, Stephen A.
    Fossati, Nicola
    Gandaglia, Giorgio
    Tian, Zhe
    Moschini, Marco
    Capitanio, Umberto
    Karakiewicz, Pierre I.
    Montorsi, Francesco
    Karnes, R. Jeffrey
    Briganti, Alberto
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 27 - 34
  • [28] Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy: the usefulness of PSA doubling time
    Numata, K
    Azuma, K
    Hashine, K
    Sumiyoshi, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (05) : 256 - 259
  • [29] PSA doubling time is not a surrogate for prostate-cancer-specific survival
    Nature Clinical Practice Oncology, 2007, 4 (2): : 69 - 69
  • [30] Time without PSA recurrence after radical prostatectomy as a predictor of prostate cancer death
    Ahlberg, M.
    Garmo, H.
    Adami, H-O
    Andren, O.
    Johansson, J-E
    Steineck, G.
    Holmberg, L.
    Bill-Axelson, A.
    EUROPEAN UROLOGY, 2022, 81 : S286 - S286